167 related articles for article (PubMed ID: 33875093)
1. Bovine Serum Albumin Nanoparticle-Mediated Delivery of Sorafenib for Improving Hepatocellular Carcinoma Therapy.
Ming Y; Li B; Fu R; Xing H; Liu Y; Duan D; Li Z; Li L; Ni R; Xu J; Li C; Xiang M; Song H; Chen J
J Nanosci Nanotechnol; 2021 Oct; 21(10):5075-5082. PubMed ID: 33875093
[TBL] [Abstract][Full Text] [Related]
2. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
3. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Yu XN; Deng Y; Zhang GC; Liu J; Liu TT; Dong L; Zhu CF; Shen XZ; Li YH; Zhu JM
ACS Appl Mater Interfaces; 2020 Apr; 12(15):17193-17206. PubMed ID: 32207914
[TBL] [Abstract][Full Text] [Related]
5. Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Elsayed MM; Mostafa ME; Alaaeldin E; Sarhan HA; Shaykoon MS; Allam S; Ahmed AR; Elsadek BE
Int J Nanomedicine; 2019; 14():8445-8467. PubMed ID: 31754301
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
Phan C; Zheng Z; Wang J; Wang Q; Hu X; Tang G; Bai H
Biomater Sci; 2019 Nov; 7(11):4758-4768. PubMed ID: 31509117
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
9. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
10. Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.
Li S; Xu L; Wu G; Huang Z; Huang L; Zhang F; Wei C; Shen Q; Li R; Zhang L; Xu X
Adv Sci (Weinh); 2023 Jul; 10(19):e2207118. PubMed ID: 37203277
[TBL] [Abstract][Full Text] [Related]
11. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
12. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cytotoxic activity of sorafenib-loaded camel milk casein nanoparticles against hepatocarcinoma cells.
Mittal A; Mahala N; Dhanawade NH; Dubey SK; Dubey US
Biotechnol J; 2024 Mar; 19(3):e2300449. PubMed ID: 38472095
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
15. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
[TBL] [Abstract][Full Text] [Related]
19. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
